« Return to News | CROs/Service Providers

Chiltern Expands in Asia-Pacific

Friday, May 21, 2010 09:05 AM

UK-based contract research organization (CRO)  Chiltern has announced its expansion plans in Asia-Pacific. 

Chiltern has established two new offices and launched operations in Australia and Singapore–with Singapore acting as the hub for its operations in Southeast Asia. This builds further upon Chiltern’s well established operation in India. Chiltern is also establishing operations in China.

Chiltern’s Asia-Pacific operations will be led by Umakanta Sahoo, Executive Director, Asia-Pacific. “Chiltern’s expansion will provide a broad platform from which global pharmaceutical and biotech Sponsors can expand their geographic reach with confidence and enhance patient recruitment in the Asia-Pacific region,” stated Sahoo.

Glenn Kerkhof, Chiltern’s CEO, stated, “Asia-Pacific is one of the foremost emerging markets in our industry. With the current expansion of pharmaceutical R & D needs into the Asia-Pacific region, Chiltern is well positioned to meet the needs this growth entails. We are very pleased to provide our clients with access to this market while extending our focus on the delivery of high quality, responsive and better value services to our customers.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.